Indivior (INDV) AI Stock Analysis

• Market Cap: £1.95B
• Dividend Yield: N/A
• Average Volume (3M): 1.89M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 4.09%
• EPS Growth: -640.24%
• Country: US
• Employees: 1,030
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.41
• Shares Outstanding: 124,769,530
• 10 Day Avg. Volume: 1,340,353
• 30 Day Avg. Volume: 1,893,981
• PEG Ratio: 3.47
• Price to Book (P/B): -6.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.56
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 0.41
• Enterprise Value/Gross Profit: 2.09
• Enterprise Value/Ebitda: 14.13
• 1Y Price Target: £17.94
• Price Target Upside: 11.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 68 Neutral
• Price Target: $17.00 ▲(5.20%Upside)

Indivior's overall stock score reflects a mix of strong technical momentum and positive financial trends, offset by valuation challenges and revenue pressures. The company's operational improvements and strategic appointments provide optimism, but caution is warranted due to negative equity and competitive pressures.

Positive Factors

Cost Management

The company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.

Financial Performance

1Q25 group results beat expectations, with revenues declining a more modest 6% compared to a 14% expected decline.

Market Position

Sublocade retains a dominant market share with approximately 80% share within the cohort for buprenorphine-based LAI and 60% share of LAI-naive patients.

Negative Factors

Earnings Guidance

FY25 Sublocade guidance has been set at $725-765m, implying a broadly flat outlook due to ongoing funding issues within CJS.

Funding Challenges

CJS funding gaps remain a key headwind, affecting Sublocade sales and contributing to a 38% decline in the CJS market.

Market Competition

A 5th generic from Teva has not yet reached the market, indicating increasing generic pricing pressure.

Indivior Business Overview & Revenue Model

Company Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

How the Company Makes Money

Indivior makes money primarily through the sale of its pharmaceutical products designed for the treatment of addiction, with a significant portion of its revenue coming from its flagship product, Suboxone. The company generates revenue by selling its products to healthcare providers, pharmacies, and government health programs. Indivior also invests in research and development to create new treatments and improve existing ones, which can lead to additional revenue streams as these innovations reach the market. Strategic partnerships and collaborations with healthcare organizations and government bodies also contribute to its earnings, as they expand the company's reach and market penetration. Additionally, Indivior's global operations allow it to leverage diverse markets, further driving its revenue growth.

Indivior Financial Statement Overview

Summary

Indivior demonstrates a positive financial trajectory with substantial revenue growth and improving profitability. The income statement reflects strong recovery, while the cash flow statement highlights improved cash generation. However, the negative equity position and low EBIT margin are key areas of concern that need attention.

Income Statement

Indivior's income statement shows a strong recovery and growth trend, with a significant increase in total revenue from $647M in 2020 to $1.17B in TTM. The company achieved a positive net income in TTM after a period of losses, indicating improved profitability. Gross profit margins have remained strong, and the net profit margin turned positive in TTM, reflecting effective cost management. However, the EBIT margin is relatively low, suggesting potential areas for operational efficiency improvements.

Balance Sheet

The balance sheet reveals a negative stockholders' equity position in TTM, which is a significant weakness, as it suggests more liabilities than assets. Despite this, the company has managed its debt levels well, with a low total debt. The equity ratio is negative, reflecting the need for strengthening equity capital. However, the low debt-to-equity ratio indicates that the company is not heavily leveraged, which is a positive aspect.

Cash Flow

Cash flow analysis shows a significant improvement in operating cash flow, turning positive in TTM. Free cash flow has also grown substantially, reflecting strong cash generation capabilities. The operating cash flow to net income ratio is robust, indicating efficient cash management. However, the fluctuation in free cash flow over the years points to potential volatility in cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.19B	1.09B	884.63M	777.48M	689.68M
Gross Profit	957.00M	907.00M	715.75M	639.87M	573.49M
EBITDA	84.00M	68.61M	-44.18M	233.93M	-128.98M
Net Income	2.00M	2.00M	-52.04M	205.00M	-157.76M
Balance Sheet
Total Assets	1.32B	1.95B	1.78B	1.83B	1.53B
Cash, Cash Equivalents and Short-Term Investments	320.00M	410.00M	897.83M	1.10B	858.00M
Total Debt	375.00M	282.00M	278.50M	285.44M	285.00M
Total Liabilities	1.67B	1.95B	1.73B	1.63B	1.45B
Stockholders Equity	-348.00M	67.90M	51.28M	202.60M	82.00M
Cash Flow
Free Cash Flow	7.00M	-368.00M	-9.82M	313.55M	-210.00M
Operating Cash Flow	36.00M	-315.00M	-3.93M	346.97M	-205.73M
Investing Cash Flow	69.00M	-100.36M	-218.95M	-13.76M	-4.26M
Financing Cash Flow	-102.00M	-46.00M	-98.18M	-92.39M	-10.66M

Indivior Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDV, the sentiment is Positive. The current price of 16.16 is above the 20-day moving average (MA) of 14.84, above the 50-day MA of 13.34, and above the 200-day MA of 11.08, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 73.83 is Negative, neither overbought nor oversold. The STOCH value of 72.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDV.

Indivior Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPN	72 Outperform	$1.88B	30.41	6.32%	―	11.82%	―
ANIP	71 Outperform	$1.44B	―	-5.19%	―	30.26%	-173.36%
AMPH	69 Neutral	$1.00B	7.88	19.90%	―	8.05%	-8.46%
INDV	68 Neutral	£1.95B	―		―	4.09%	-640.24%
PCRX	60 Neutral	$1.05B	―	-12.27%	―	3.08%	-247.82%
Sector *	60 Neutral	HK$16.23B	5.53	-7.44%	3.84%	11.55%	-28.15%
EVO	49 Neutral	$1.50B	―	-20.41%	―	0.45%	-125.61%

Indivior Corporate Events

Indivior Appoints Tony Kingsley as Non-Executive Director

On June 24, 2025, Indivior PLC announced the appointment of Tony Kingsley as a non-executive director, effective July 1, 2025. Kingsley, an accomplished biopharmaceutical executive, is expected to bring significant commercial and clinical development experience to Indivior, enhancing its efforts to advance its mission and strengthen its position in delivering treatments for opioid use disorder. His appointment aligns with Indivior’s relationship agreement with affiliates of Oaktree Capital Management, and he will be compensated in line with other non-executive directors.

The most recent analyst rating on (INDV) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.